DCR-MYC

DRUG2 trials

Sponsors

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Conditions

Hepatocellular CarcinomaMultiple MyelomaNHLNon-Hodgkins LymphomaPNETPancreatic Neuroendocrine TumorsSolid Tumors

Phase 1

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

TerminatedNCT02110563

Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyMultiple Myeloma, NHL, Non-Hodgkins Lymphoma +3

Start: 2014-04-30End: 2016-11-03Updated: 2024-07-11

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma

TerminatedNCT02314052

Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyHepatocellular Carcinoma

Start: 2015-01-27End: 2016-10-11Updated: 2024-07-11

Related Papers

Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing

Molecular Case Studies2017-11-0143 citations

Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors.

Journal of Clinical Oncology2015-05-20116 citations